Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics (Nasdaq: CCCC) announced that the European Society for Medical Oncology (ESMO) Congress has upgraded their previously accepted preliminary Phase 1 abstract for CFT1946, a novel BiDAC™ degrader for mutant BRAF V600 solid tumors, to an oral presentation. The presentation is scheduled for September 13, 2024, at 4:00 pm to 5:30 pm CEST. Dr. Maria Vieito from Barcelona will present the preliminary results from the Phase 1 study. C4T will also host an investor webcast on the same day to discuss the CFT1946 monotherapy data from the ongoing trial. This change in presentation format suggests increased interest in C4T's research, potentially indicating promising preliminary results for their targeted protein degradation approach in oncology.
C4 Therapeutics (Nasdaq: CCCC) reported Q2 2024 financial results and business highlights. Key points include:
- Preliminary CFT1946 Phase 1 data for BRAF V600X solid tumors to be presented at ESMO Congress 2024
- Cemsidomide Phase 1 trial progressing; data expected in Q4 2024
- Cash position of $295.7 million as of June 30, 2024, providing runway into 2027
- Q2 2024 revenue: $12.0 million, up from $2.7 million in Q2 2023
- Q2 2024 net loss: $17.7 million, improved from $35.9 million in Q2 2023
- Net loss per share: $0.26, compared to $0.73 in Q2 2023
The company continues to advance its clinical programs and expects multiple data readouts in H2 2024.
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The presentation, titled 'Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors,' will be delivered as a mini oral presentation on September 14, 2024. This presentation marks an important milestone in C4 Therapeutics' development of targeted protein degradation therapies and could provide valuable insights into the potential efficacy of CFT1946 in treating BRAF V600 mutant solid tumors.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, will participate in the UBS Targeted Protein Degradation Day, held virtually on July 15, 2024. The company's management will engage in a fireside chat from 12:00 pm ET to 12:30 pm ET. A live webcast of the event will be accessible on the Investors section of C4 Therapeutics' website, with a replay available for 30 days post-event.
C4 Therapeutics has appointed Ron Cooper as the new Chairman of the Board.
He brings extensive global pharmaceutical and biotechnology experience.
Bruce Downey will remain on the Board and chair the Organization, Leadership, and Compensation Committee.
Glenn Dubin is stepping down from the Board.
C4 Therapeutics aims to become a fully integrated biotechnology company, focusing on targeted protein degradation science.
Ron Cooper's past roles include leadership positions at Albireo Pharma and Bristol-Myers Squibb.
His experience spans across discovery, development, and commercialization of pharmaceutical products.
CEO Andrew Hirsch expressed excitement about Cooper's appointment and the future growth of C4 Therapeutics.
C4 Therapeutics, a biopharmaceutical company, reported strong financial results for the first quarter of 2024. They earned an $8 million payment from Biogen, established a research collaboration with Merck KGaA, and advanced Phase 1 trials for CFT7455 and CFT1946. The company's cash position stood at $299.2 million, providing runway into 2027.
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
